Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Dupixent patent cliff?

See the DrugPatentWatch profile for Dupixent

Dupixent (dupilumab) – The “Patent Cliff” Explained

Item Detail Notes
Drug Dupixent® (dupilumab) Human monoclonal antibody that blocks the IL‑4 receptor α subunit; approved 2017 for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and other indications.
Key Patent Family 3 core “method‑of‑treating” patents + 7+ formulation & device patents The family includes US 2008/0171666, US 2009/059913, US 2011/


Other Questions About Dupixent :

Can you specify the quarters with dupixent sales growth in 2020? In which specific quarters did dupixent s sales see a rise in 2020? What percentage of sanofi and regeneron s total revenue did dupixent generate in 2020? In which quarters did dupixent sales increase in 2020? How much revenue did dupixent generate in 2020? How much did dupixent s 2020 revenue increase from the previous year? What were sales of dupixent in 2020?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Medium

Summary

No specific AI-generated drug-label claim content was provided for evaluation against the supplied FDA label excerpts; as a result, alignment cannot be verified and the requested comparison is effectively non-auditable.


Category Scores


Accurate Statements

The evaluator states it cannot determine supported/contradicted status because no specific user claim text was provided.
No direct label mapping possible; this is a meta-statement about missing claim input rather than a drug-label claim.

Unsupported Statements

The evaluator asserts 'Supported: no' and 'Contradicted: no' without providing any user claim text to map to labeling.
These conclusions are not supportable from the provided FDA label excerpts because no claim was specified to evaluate.

Contradictions


Important Omissions

Exact user claim(s) and any AI-generated claim(s) to be audited for support/contradiction against specific label language.
Importance: High

Safety Assessment

Potential Patient Risk: Medium
The audit output provides ungrounded 'Supported/Contradicted' determinations despite missing claim text, which could mislead downstream decisions about label compliance.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
Determinations of supported/contradicted status were made without any claim content to compare against the FDA label.

Suggested Improvement
Provide the exact AI/user claim text (1–2 sentences) and then map each assertion to the specific FDA label section(s)/sentences before concluding supported vs. contradicted.

Drug Brand Mention Assessment

Branding Score
52
Visibility
56
Mentioned
Ranking
#1
Sentiment
58
Recommendation Status
mentioned only
Brand Perception
Best Known For

Dupixent (dupilumab) has multiple overlapping patent and exclusivity timelines


Core Claims
  • Dupixent has multiple overlapping patent and exclusivity timelines tied to specific jurisdictions and formulations
  • The “patent cliff” usually refers to the point when key patents expire
  • The practical cliff is not a single date everywhere
  • Dupixent’s revenue outlook is sensitive to the start of biosimilar competition
Differentiators
  • Protection comes from a web of patent families covering the molecule, therapeutic use, and manufacturing or formulation details
  • Competitive entry may arrive in phases rather than all at once

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
AbbVie 10%
58 #2 No
Regeneron 10%
58 #3 No